TERN insider transaction filings
Terns Pharmaceuticals, Inc. — 46 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-05-05. Screen TERN transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-05 | 4 | Kuriakose Emil — Chief Medical Officer | Code (U): 24,562 @ $53 · Disposition to issuer (D): 81,953 @ $53 · Disposition to issuer (D): 485,000 (derivative) · Disposition to issuer (D): 117,500 (derivative) · Disposition to issuer (D): 120,000 (derivative) · Disposition to issuer (D): 280,000 (derivative) · +1 more | EDGAR |
| 2026-05-05 | 4 | Burroughs Amy L. — Chief Executive Officer, Director | Code (U): 146,614 @ $53 · Code (U): 8,319 @ $53 · Disposition to issuer (D): 150,000 @ $53 · Disposition to issuer (D): 955,534 (derivative) · Disposition to issuer (D): 1,250,000 (derivative) · Disposition to issuer (D): 300,000 (derivative) | EDGAR |
| 2026-05-05 | 4 | Quigley Jill M. — Director | Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 10,657 (derivative) · Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 3,955 (derivative) · Disposition to issuer (D): 22,000 (derivative) · Disposition to issuer (D): 32,000 (derivative) · +1 more | EDGAR |
| 2026-05-05 | 4 | Tripuraneni Radhika — Director | Disposition to issuer (D): 64,000 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 10,657 (derivative) · Disposition to issuer (D): 4,676 (derivative) · Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 32,000 (derivative) · +1 more | EDGAR |
| 2026-05-05 | 4 | Azelby Robert — Director | Disposition to issuer (D): 90,000 (derivative) · Disposition to issuer (D): 1,697 (derivative) | EDGAR |
| 2026-05-05 | 4 | Gengos Andrew — Chief Financial Officer | Code (U): 40,503 @ $53 · Disposition to issuer (D): 68,750 @ $53 · Disposition to issuer (D): 750,000 (derivative) · Disposition to issuer (D): 137,500 (derivative) | EDGAR |
| 2026-05-05 | 4 | Turner Heather D — Director | Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 64,000 (derivative) · Disposition to issuer (D): 1,697 (derivative) | EDGAR |
| 2026-05-05 | 4 | KINDLER JEFFREY B — Director | Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 10,657 (derivative) · Disposition to issuer (D): 4,676 (derivative) · Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 28,475 (derivative) · +3 more | EDGAR |
| 2026-05-05 | 4 | FELLOWS DAVID A — Director | Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 18,650 (derivative) · Disposition to issuer (D): 8,183 (derivative) · Disposition to issuer (D): 32,000 (derivative) · Disposition to issuer (D): 28,475 (derivative) · +3 more | EDGAR |
| 2026-04-02 | 4 | Kuriakose Emil — Chief Medical Officer | Sale (S): 942 @ $52.75 | EDGAR |
| 2026-03-17 | 4 | Burroughs Amy L. — Chief Executive Officer, Director | Option exercise (M): 14,583 @ $4.64 · Sale (S): 11,813 @ $46.57 · Sale (S): 2,770 @ $47.30 · Option exercise (M): 14,583 (derivative) @ $0 | EDGAR |
| 2026-02-18 | 4 | Burroughs Amy L. — Chief Executive Officer, Director | Option exercise (M): 14,583 @ $4.64 · Sale (S): 2,341 @ $38.07 · Sale (S): 8,159 @ $39.22 · Sale (S): 4,083 @ $39.80 · Option exercise (M): 14,583 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Quigley Jill M. — Director | Grant/award (A): 1,697 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Tripuraneni Radhika — Director | Grant/award (A): 1,697 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Azelby Robert — Director | Grant/award (A): 1,697 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | Turner Heather D — Director | Grant/award (A): 1,697 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | KINDLER JEFFREY B — Director | Grant/award (A): 1,697 (derivative) @ $0 | EDGAR |
| 2026-02-02 | 4 | FELLOWS DAVID A — Director | Grant/award (A): 2,828 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Kuriakose Emil — Chief Medical Officer | Grant/award (A): 56,250 @ $0 · Grant/award (A): 112,500 (derivative) @ $0 | EDGAR |
| 2026-01-16 | 4 | Burroughs Amy L. — Chief Executive Officer, Director | Grant/award (A): 150,000 @ $0 · Option exercise (M): 27,083 @ $4.64 · Option exercise (M): 27,083 @ $4.64 · Option exercise (M): 14,583 @ $4.64 · Sale (S): 61,228 @ $37.02 · Sale (S): 7,521 @ $37.53 · +4 more | EDGAR |
| 2026-01-16 | 4 | Gengos Andrew — Chief Financial Officer | Grant/award (A): 68,750 @ $0 · Grant/award (A): 137,500 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Kuriakose Emil — Chief Medical Officer | Sale (S): 200 @ $39.60 · Sale (S): 955 @ $38.36 | EDGAR |
| 2026-01-06 | 4 | Burroughs Amy L. — Chief Executive Officer, Director | Option exercise (M): 21,551 @ $4.64 · Option exercise (M): 150,000 · Sale (S): 71,339 @ $38.10 · Option exercise (M): 21,551 (derivative) @ $0 · Option exercise (M): 150,000 (derivative) @ $0 | EDGAR |
| 2025-11-05 | 4 | Quigley Jill M. — Director | Option exercise (M): 24,520 @ $9.24 · Sale (S): 24,520 @ $18 · Option exercise (M): 24,520 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Kuriakose Emil — Chief Medical Officer | Sale (S): 944 @ $7.85 | EDGAR |
| 2025-07-03 | 4 | Kuriakose Emil — Chief Medical Officer | Sale (S): 853 @ $4.27 | EDGAR |
| 2025-06-30 | 4 | Gengos Andrew — Chief Financial Officer | Purchase (P): 5,000 @ $3.93 · Purchase (P): 5,000 @ $3.93 | EDGAR |
| 2025-06-25 | 4 | Burroughs Amy L. — Chief Executive Officer, Director | Purchase (P): 23,314 @ $3.87 | EDGAR |
| 2025-06-16 | 4 | Gengos Andrew — Chief Financial Officer | Purchase (P): 5,000 @ $3.75 · Purchase (P): 5,000 @ $3.72 · Purchase (P): 5,000 @ $3.95 | EDGAR |
| 2025-06-12 | 4 | Quigley Jill M. — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Lu Hongbo — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Tripuraneni Radhika — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Turner Heather D — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | KINDLER JEFFREY B — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | FELLOWS DAVID A — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | Kuriakose Emil — Chief Medical Officer | Sale (S): 952 @ $2.49 | EDGAR |
| 2025-02-25 | 4 | Gengos Andrew — Chief Financial Officer | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Azelby Robert — Director | Grant/award (A): 90,000 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Jung Melita Sun — Chief Business Officer | Purchase (P): 2,250 @ $5.11 · Grant/award (A): 325,000 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Kuriakose Emil — Chief Medical Officer | Grant/award (A): 485,000 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Burroughs Amy L. — Chief Executive Officer, Director | Purchase (P): 510 @ $5.11 · Grant/award (A): 1,075,000 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Quigley Jill M. — Director | Grant/award (A): 10,657 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Lu Hongbo — Director | Grant/award (A): 10,657 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | Tripuraneni Radhika — Director | Grant/award (A): 10,657 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | KINDLER JEFFREY B — Director | Grant/award (A): 10,657 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | FELLOWS DAVID A — Director | Grant/award (A): 18,650 (derivative) @ $0 | EDGAR |
Recent 8-K events — Terns Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-05-05 | 8-K | 2.01 — Completion of Acquisition or Disposition of Assets 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 3.03 — Material Modification to Rights of Security Holders 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
| 2026-01-09 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-08 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-03 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-22 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TERN returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →